Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism.

Klok FA, Presles E, Tromeur C, Barco S, Konstantinides SV, Sanchez O, Pernod G, Raj L, Robin P, Le Roux PY, Hoffman C, Mélac S, Bertoletti L, Girard P, Laporte S, Mismetti P, Meyer G, Leroyer C, Couturaud F; PADIS‐PE Investigators.

Res Pract Thromb Haemost. 2019 May 25;3(3):364-371. doi: 10.1002/rth2.12214. eCollection 2019 Jul.

2.

Synergistic application of pulmonary 18F-FDG PET/HRCT and computer-based CT analysis with conventional severity measures to refine current risk stratification in idiopathic pulmonary fibrosis (IPF).

Fraioli F, Lyasheva M, Porter JC, Bomanji J, Shortman RI, Endozo R, Wan S, Bertoletti L, Machado M, Ganeshan B, Win T, Groves AM.

Eur J Nucl Med Mol Imaging. 2019 Jul 8. doi: 10.1007/s00259-019-04386-5. [Epub ahead of print]

PMID:
31286201
3.

[Recommendations for best practice in the management of venous thromboembolic disease in adults. Long version].

Sanchez O, Benhamou Y, Bertoletti L, Constans J, Couturaud F, Delluc A, Elias A, Fischer AM, Frappé P, Gendron N, Girard P, Godier A, Gut-Gobert C, Laporte S, Mahé I, Mauge L, Meneveau N, Meyer G, Mismetti P, Parent F, Pernod G, Quéré I, Revel MP, Roy PM, Salaün PY, Smadja DM, Sevestre MA.

Rev Mal Respir. 2019 Jul 4. pii: S0761-8425(19)30210-4. doi: 10.1016/j.rmr.2019.05.038. [Epub ahead of print] French. No abstract available.

PMID:
31280989
4.

Pulmonary hypertension due to pulmonary artery obstructions by malignant tumoral cells.

Murgier M, Forest F, Savale L, Ilie M, Bertoletti L.

Respir Med Res. 2019 Apr 30;76:10-12. doi: 10.1016/j.resmer.2019.04.006. [Epub ahead of print] No abstract available.

PMID:
31254944
5.

Predictors for Residual Pulmonary Vascular Obstruction after Unprovoked Pulmonary Embolism: Implications for Clinical Practice-The PADIS-PE Trial.

Raj L, Robin P, Le Mao R, Presles E, Tromeur C, Sanchez O, Pernod G, Bertoletti L, Jego P, Leven F, Lemarié CA, Martin A, Planquette B, Le Roux PY, Salaun PY, Nonent M, Girard P, Lacut K, Melac S, Mismetti P, Laporte S, Meyer G, Leroyer C, Couturaud F; PADIS-PE Investigators.

Thromb Haemost. 2019 Jun 23. doi: 10.1055/s-0039-1692424. [Epub ahead of print]

PMID:
31230343
6.

Erratum à « Unresolved questions on venous thromboembolic disease. Consensus statement of the French Society for Vascular Medicine (SFMV) » [J. Med. Vasc. 44 (2019) 28–70].

Quéré I, Elias A, Maufus M, Elias M, Sevestre MA, Galanaud JP, Bosson JL, Bura-Rivière A, Jurus C, Lacroix P, Zuily S, Diard A, Wahl D, Bertoletti L, Brisot D, Frappe P, Gillet JL, Ouvry P, Pernod G.

J Med Vasc. 2019 Jun;44(4):307-308. doi: 10.1016/j.jdmv.2019.04.009. Epub 2019 May 15. French. No abstract available.

PMID:
31213305
7.

Extended Anticoagulation for VTE: A Systematic Review and Meta-Analysis.

Mai V, Guay CA, Perreault L, Bonnet S, Bertoletti L, Lacasse Y, Jardel S, Lega JC, Provencher S.

Chest. 2019 Jun;155(6):1199-1216. doi: 10.1016/j.chest.2019.02.402.

PMID:
31174635
8.

Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry.

Murgier M, Bertoletti L, Darmon M, Zeni F, Valle R, Del Toro J, Llamas P, Mazzolai L, Villalobos A, Monreal M; RIETE Investigators.

Int J Cardiol. 2019 Sep 15;291:121-126. doi: 10.1016/j.ijcard.2019.04.083. Epub 2019 May 21.

PMID:
31147192
9.

Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study.

Kraaijpoel N, Bleker SM, Meyer G, Mahé I, Muñoz A, Bertoletti L, Bartels-Rutten A, Beyer-Westendorf J, Porreca E, Boulon C, van Es N, Iosub DI, Couturaud F, Biosca M, Lerede T, Lacroix P, Maraveyas A, Aggarwal A, Girard P, Büller HR, Di Nisio M; UPE investigators.

J Clin Oncol. 2019 Jul 10;37(20):1713-1720. doi: 10.1200/JCO.18.01977. Epub 2019 May 22.

PMID:
31116676
10.

Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?

Margelidon-Cozzolino V, Delavenne X, Catella-Chatron J, De Magalhaes E, Bezzeghoud S, Humbert M, Montani D, Bertoletti L.

Blood Rev. 2019 May 15. pii: S0268-960X(19)30019-0. doi: 10.1016/j.blre.2019.05.003. [Epub ahead of print] Review.

PMID:
31113643
11.

Cancer incidence in patients with pre-capillary pulmonary hypertension.

Bravos E, Cottin V, Dauphin C, Bouvaist H, Traclet J, Trésorier R, Margelidon-Cozzolino V, Bezzeghoud S, Ahmad K, Accassat S, De Magalhaes E, Mornex JF, Pison C, Bertoletti L.

J Heart Lung Transplant. 2019 Jul;38(7):778-780. doi: 10.1016/j.healun.2019.03.007. Epub 2019 Mar 15. No abstract available.

PMID:
30962146
12.

Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.

Mai V, Bertoletti L, Cucherat M, Jardel S, Grange C, Provencher S, Lega JC.

PLoS One. 2019 Apr 1;14(4):e0214134. doi: 10.1371/journal.pone.0214134. eCollection 2019.

13.

Direct oral anticoagulants for venous thromboembolism prophylaxis in critically ill patients: where do we go from here?

Bertoletti L, Murgier M, Stelfox HT.

Intensive Care Med. 2019 Apr;45(4):549-551. doi: 10.1007/s00134-019-05605-1. Epub 2019 Mar 25. No abstract available.

PMID:
30911805
14.

Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism.

van der Pol LM, Tromeur C, Bistervels IM, Ni Ainle F, van Bemmel T, Bertoletti L, Couturaud F, van Dooren YPA, Elias A, Faber LM, Hofstee HMA, van der Hulle T, Kruip MJHA, Maignan M, Mairuhu ATA, Middeldorp S, Nijkeuter M, Roy PM, Sanchez O, Schmidt J, Ten Wolde M, Klok FA, Huisman MV; Artemis Study Investigators.

N Engl J Med. 2019 Mar 21;380(12):1139-1149. doi: 10.1056/NEJMoa1813865.

PMID:
30893534
15.

[Recommendations of good practice for the management of thromboembolic venous disease in adults. Short version].

Sanchez O, Benhamou Y, Bertoletti L, Constant J, Couturaud F, Delluc A, Elias A, Fischer AM, Frappé P, Gendron N, Girard P, Godier A, Gut-Gobert C, Laporte S, Mahé I, Mauge L, Meneveau N, Meyer G, Mismetti P, Parent F, Pernod G, Quéré I, Revel MP, Roy PM, Salaün PY, Smadja DM, Sevestre MA.

Rev Mal Respir. 2019 Feb;36(2):249-283. doi: 10.1016/j.rmr.2019.01.003. Epub 2019 Feb 22. French. No abstract available.

PMID:
30799126
16.

[Unresolved questions on venous thromboembolic disease. Consensus statement of the French Society for Vascular Medicine (SFMV)].

Quéré I, Elias A, Maufus M, Elias M, Sevestre MA, Galanaud JP, Bosson JL, Bura-Rivière A, Jurus C, Lacroix P, Zuily S, Diard A, Wahl D, Bertoletti L, Brisot D, Frappe P, Gillet JL, Ouvry P, Pernod G.

J Med Vasc. 2019 Feb;44(1):e1-e47. doi: 10.1016/j.jdmv.2018.12.178. Epub 2019 Feb 2. French. No abstract available.

PMID:
30770089
17.

Unresolved questions on venous thromboembolic disease. Consensus statement of the French Society for Vascular Medicine (SFMV).

Quéré I, Elias A, Maufus M, Elias M, Sevestre MA, Galanaud JP, Bosson JL, Bura-Rivière A, Jurus C, Lacroix P, Zuily S, Diard A, Wahl D, Bertoletti L, Brisot D, Frappe P, Gillet JL, Ouvry P, Pernod G.

J Med Vasc. 2019 Feb;44(1):28-70. doi: 10.1016/j.jdmv.2018.12.003. Epub 2019 Jan 23. No abstract available. Erratum in: J Med Vasc. 2019 Jun;44(4):307-308.

PMID:
30770082
18.

The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease.

Jiménez D, Agustí A, Monreal M, Otero R, Huisman MV, Lobo JL, Quezada A, Jara-Palomares L, Hernando A, Tabernero E, Marcos P, Ruiz-Artacho P, Ballaz A, Bertoletti L, Couturaud F, Yusen R; SLICE investigators.

Clin Cardiol. 2019 Mar;42(3):346-351. doi: 10.1002/clc.23161. Epub 2019 Feb 25.

19.

Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial.

Couturaud F, Pernod G, Presles E, Duhamel E, Jego P, Provost K, Pan-Petesch B, Sollier CBD, Tromeur C, Hoffmann C, Bressollette L, Lorillon P, Girard P, Le Moigne E, Le Hir A, Guégan M, Laporte S, Mismetti P, Lacut K, Bosson JL, Bertoletti L, Sanchez O, Meyer G, Leroyer C, Mottier D; “PADIS-DVT” investigators.

Haematologica. 2019 Jul;104(7):1493-1501. doi: 10.3324/haematol.2018.210971. Epub 2019 Jan 3.

20.

Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial.

Barco S, Russo M, Vicaut E, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Danays T, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Klok FA, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G, Konstantinides SV.

Clin Res Cardiol. 2019 Jul;108(7):772-778. doi: 10.1007/s00392-018-1405-1. Epub 2018 Dec 18.

21.

[Risk factors for thromboembolic disease in young women-the role of hormones].

Tromeur C, Le Mao R, Jego P, El-Kouri D, Gruel Y, Pan-Petesch B, Bertoletti L, Morange PE, Lemoigne E, Paleiron N, Leroyer C, Couturaud F.

Rev Mal Respir. 2019 Feb;36(2):219-226. doi: 10.1016/j.rmr.2018.05.013. Epub 2018 Oct 11. French.

PMID:
30318429
22.

Ruling out deep vein thrombosis in patients with superficial vein thrombosis: external validation of the ICARO score.

Frappé P, Brosse Q, Seffert B, Décousus H, Bertoletti L; STEPH Study Group.

J Thromb Thrombolysis. 2019 Jan;47(1):96-101. doi: 10.1007/s11239-018-1754-7.

PMID:
30317413
23.

Benefit of Risk Score-Guided Prophylaxis in Pregnant Women at Risk of Thrombotic Events: A Controlled Before-and-After Implementation Study.

Chauleur C, Gris JC, Laporte S, Chapelle C, Bertoletti L, Equy V, Gaucherand P, Bazan E, Dupuis O, Gallot D, Mismetti P; STRATHEGE Investigators and The STRATHEGE Group.

Thromb Haemost. 2018 Sep;118(9):1564-1571. doi: 10.1055/s-0038-1668524. Epub 2018 Aug 13.

PMID:
30103244
24.

Screening cancer after venous thromboembolism: How many abnormal tests before diagnosing cancer? An analysis of practice.

Duvillard C, De Magalhaes E, Moulin N, Accassat S, Mismetti P, Bertoletti L.

Presse Med. 2018 Jul - Aug;47(7-8 Pt 1):e99-e106. doi: 10.1016/j.lpm.2018.01.026. Epub 2018 Jul 31.

PMID:
30075951
25.

Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP).

Decousus H, Bourmaud A, Fournel P, Bertoletti L, Labruyère C, Presles E, Merah A, Laporte S, Stefani L, Piano FD, Jacquin JP, Meyer G, Chauvin F; ONCOCIP Investigators.

Blood. 2018 Aug 16;132(7):707-716. doi: 10.1182/blood-2018-03-837153. Epub 2018 Jul 6.

PMID:
29980524
26.

Prognosis of venous thromboembolism in orthopaedic surgery or trauma patients and use of thromboprophylaxis.

Gutiérrez Guisado J, Trujillo-Santos J, Arcelus JI, Bertoletti L, Fernandez-Capitán C, Valle R, Hernandez-Hermoso JA, Erice Calvo-Sotelo A, Nieto JA, Monreal M; en nombre de los investigadores del estudio RIETE.

Rev Clin Esp. 2018 Nov;218(8):399-407. doi: 10.1016/j.rce.2018.04.018. English, Spanish.

PMID:
29929734
27.

Outcomes following a negative computed tomography pulmonary angiography according to pulmonary embolism prevalence: a meta-analysis of the management outcome studies.

Belzile D, Jacquet S, Bertoletti L, Lacasse Y, Lambert C, Lega JC, Provencher S.

J Thromb Haemost. 2018 Jun;16(6):1107-1120. doi: 10.1111/jth.14021. Epub 2018 May 17.

PMID:
29645405
28.

In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein.

Margelidon-Cozzolino V, Hodin S, Jacqueroux E, Delézay O, Bertoletti L, Delavenne X.

J Pharmacol Exp Ther. 2018 Jun;365(3):519-525. doi: 10.1124/jpet.117.245993. Epub 2018 Mar 23.

PMID:
29572341
29.

Role of a clinical prediction score in a chronic thromboembolic pulmonary hypertension rule-out strategy.

Otero R, Bertoletti L, Muriel A, Siniscalchi C, Jimenez C, Luis Lobo J, Kigitovica D, Quintavalla R, Rocci A, Jara-Palomares L, Monreal M; RIETE Investigators.

Eur Respir J. 2018 Apr 19;51(4). pii: 1702576. doi: 10.1183/13993003.02576-2017. Print 2018 Apr. No abstract available.

PMID:
29496752
30.

Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events-a meta-analysis.

Trone JC, Ollier E, Chapelle C, Bertoletti L, Cucherat M, Mismetti P, Magné N, Laporte S.

Ann Oncol. 2018 Apr 1;29(4):803-811. doi: 10.1093/annonc/mdy035.

PMID:
29415169
31.

Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review.

Bertoletti L, Benhamou Y, Béjot Y, Marechaux S, Cheggour S, Aleil B, Lellouche N, Dillinger JG, Delluc A.

Blood Rev. 2018 Jul;32(4):272-279. doi: 10.1016/j.blre.2018.01.002. Epub 2018 Apr 20. Review.

PMID:
29402471
32.

Predictors of Post-Thrombotic Ulcer after Acute DVT: The RIETE Registry.

Galanaud JP, Bertoletti L, Amitrano M, Fernández-Capitán C, Pedrajas JM, Rosa V, Barrón M, Lorenzo A, Madridano O, Quéré I, Kahn SR, Prandoni P, Monreal M; RIETE registry investigators.

Thromb Haemost. 2018 Feb;118(2):320-328. doi: 10.1160/TH17-08-0598. Epub 2018 Jan 29.

PMID:
29378357
33.

Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial.

Tromeur C, Sanchez O, Presles E, Pernod G, Bertoletti L, Jego P, Duhamel E, Provost K, Parent F, Robin P, Deloire L, Leven F, Mingant F, Bressollette L, Le Roux PY, Salaun PY, Nonent M, Pan-Petesch B, Planquette B, Girard P, Lacut K, Melac S, Mismetti P, Laporte S, Meyer G, Mottier D, Leroyer C, Couturaud F; PADIS-PE Investigators18.

Eur Respir J. 2018 Jan 4;51(1). pii: 1701202. doi: 10.1183/13993003.01202-2017. Print 2018 Jan.

34.

Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.

Chai-Adisaksopha C, Iorio A, Crowther MA, de Miguel J, Salgado E, Zdraveska M, Fernández-Capitán C, Nieto JA, Barillari G, Bertoletti L, Monreal M; RIETE investigators.

Am J Med. 2018 Apr;131(4):430-437. doi: 10.1016/j.amjmed.2017.11.042. Epub 2017 Dec 20.

PMID:
29274307
35.

Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.

Dillinger JG, Aleil B, Cheggour S, Benhamou Y, Béjot Y, Marechaux S, Delluc A, Bertoletti L, Lellouche N.

Arch Cardiovasc Dis. 2018 Feb;111(2):85-94. doi: 10.1016/j.acvd.2017.04.008. Epub 2017 Oct 2. Review.

36.

Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score.

Bertoletti L, Robin P, Jara-Palomares L, Tromeur C, Pastre J, Prevot-Bitot N, Mouneh T, Le Gal G, Salaun PY; MVTEP investigators.

J Thromb Haemost. 2017 Nov;15(11):2184-2187. doi: 10.1111/jth.13842. Epub 2017 Oct 24.

PMID:
28875565
37.

Practical issues in suspected venous thrombosis in general practice: A multicentre prospective cohort in primary care.

Bruel S, Ginzarly M, Bertoletti L, Fayard P, Chapelier E, Seffert B, Simon-Momège B, Frappé P; GUSTAVE investigators.

Thromb Res. 2017 Oct;158:19-21. doi: 10.1016/j.thromres.2017.08.002. Epub 2017 Aug 6. No abstract available.

PMID:
28800412
38.

The paradoxical association between pulmonary embolism and COPD.

Bertoletti L.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700959. doi: 10.1183/13993003.00959-2017. Print 2017 Jul. No abstract available.

39.

[Venous thromboembolic disease: Comparison of management practices in France, Italy and Spain].

Maurizot A, Bura-Rivière A, Gritli K, Bertoletti L, Hernández-Blasco L, Ciammaichella M, Díaz-Pedroche MC, Alfonso M, Lorente MA, Monreal M; RIETE Investigators.

J Med Vasc. 2017 Feb;42(1):6-13. doi: 10.1016/j.jdmv.2017.01.002. Epub 2017 Apr 18. French.

PMID:
28705449
40.

Evaluation of direct oral anticoagulants in superficial-vein thrombosis.

Frappé P, Bertoletti L, Le Hello C, Décousus H, Laporte S.

Lancet Haematol. 2017 Jun;4(6):e254. doi: 10.1016/S2352-3026(17)30062-5. No abstract available.

PMID:
28583285
41.

Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials.

Laporte S, Chapelle C, Bertoletti L, Ollier E, Zufferey P, Lega JC, Merah A, Décousus H, Schulman S, Meyer G, Cucherat M, Mismetti P.

J Thromb Haemost. 2017 Aug;15(8):1547-1558. doi: 10.1111/jth.13740. Epub 2017 Jul 5. Review.

PMID:
28544422
42.

After deep vein thrombosis, which patients refer to vascular specialist for anticoagulant withdrawal? A Delphi study results between general practitioners and vascular specialists.

Zoubian A, Bertoletti L, Frappé P.

Presse Med. 2017 May;46(5):e77-e83. doi: 10.1016/j.lpm.2016.07.026. Epub 2017 May 5.

PMID:
28483284
43.

Corrigendum to 'Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism' American Journal of Medicine 130(2017): 588-595.

Barrios D, Chavant J, Jiménez D, Bertoletti L, Rosa-Salazar V, Muriel A, Viallon A, Fernández-Capitán C, Yusen RD, Monreal M; Registro Informatizado de la Enfermedad TromboEmbólica Investigators.

Am J Med. 2017 Jul;130(7):874. doi: 10.1016/j.amjmed.2017.04.011. Epub 2017 May 5. No abstract available.

PMID:
28483061
44.

Venous thromboembolism in radiation therapy cancer patients: Findings from the RIETE registry.

Guy JB, Bertoletti L, Magné N, Rancoule C, Mahé I, Font C, Sanz O, Martín-Antorán JM, Pace F, Vela JR, Monreal M; RIETE investigators.

Crit Rev Oncol Hematol. 2017 May;113:83-89. doi: 10.1016/j.critrevonc.2017.03.006. Epub 2017 Mar 9.

PMID:
28427527
45.

Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis.

Zuily S, Domingues V, Suty-Selton C, Eschwège V, Bertoletti L, Chaouat A, Chabot F, Regnault V, Horn EM, Erkan D, Wahl D.

Autoimmun Rev. 2017 Jun;16(6):576-586. doi: 10.1016/j.autrev.2017.04.003. Epub 2017 Apr 12. Review.

PMID:
28411166
46.

Atrial fibrillation in cancer patients: Hindsight, insight and foresight.

Mery B, Guichard JB, Guy JB, Vallard A, Barthelemy JC, Da Costa A, Magné N, Bertoletti L.

Int J Cardiol. 2017 Aug 1;240:196-202. doi: 10.1016/j.ijcard.2017.03.132. Epub 2017 Apr 6. Review.

PMID:
28390744
47.

Areas of improvement in anticoagulant safety. Data from the CACAO study, a cohort in general practice.

Frappé P, Cogneau J, Gaboreau Y, Abenhaïm N, Bayen M, Calafiore M, Guichard C, Jacquet JP, Lacoin F, Bertoletti L; CACAO study investigators.

PLoS One. 2017 Apr 6;12(4):e0175167. doi: 10.1371/journal.pone.0175167. eCollection 2017.

48.

Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.

Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G.

J Am Coll Cardiol. 2017 Mar 28;69(12):1536-1544. doi: 10.1016/j.jacc.2016.12.039.

49.

Individualized treatment and proper medication

Lloret-linares C, Fares M, Lega JC, Kaguelidou F, Salvat E, Bertoletti L, Vorspan F, Daumas A.

Rev Prat. 2017 Mar 20;67(3):e141-e142. French. No abstract available.

PMID:
30688425
50.

Personalized treatment decision – Good use of risk situations

Lloret-Linares C, Fares M, Lega JC, Kaguelidou F, Salvat E, Bertoletti L, Vorspan F, Daumas A.

Rev Prat. 2017 Mar 20;67(3):e129-140. French. No abstract available.

PMID:
30688422

Supplemental Content

Loading ...
Support Center